Videos

Ruben Mesa, MD, director, UT Health San Antonio Cancer Center, discusses NCCN guideline updates in polycythemia vera and essential thrombocythemia.

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.<br /> &nbsp;

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses overcoming resistance to endocrine therapy in ER+ breast cancer.

Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.

Matthew Kulke, MD, director, Neuroendocrine and Carcinoid Tumors Program, Dana-Farber Cancer Institute, discusses treatment options on the horizon in the treatment of neuroendocrine tumors (NETs) during the 2017 NANETS Symposium.

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses the progress that has been made with monocloncal antibodies for the treatment of plasma cell neoplasms.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study that explored the different characteristics of subtypes of ovarian cancer, peritoneal tumors, and fallopian tube tumors.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing agents in chronic lymphocytic leukemia (CLL).

Celeste Lebb&eacute;, MD, from the H&ocirc;pital Saint Louis, in Paris, France, discusses the use of immunotherapy for the treatment of melanoma.

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with&nbsp;ROS1-positive non&ndash;small cell lung cancer (NSCLC).

Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Pamela L. Kunz, MD, assistant professor of medicine (oncology), Stanford University Medical Center, discusses managing the adverse event of diarrhea in patients with carcinoid syndrome, specifically with the use of telotristat ethyl (Xermelo) during the 10th Annual NANETS Symposium.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of central nervous system (CNS) activity in agents for the treatment of non&ndash;small cell lung cancer (NSCLC).

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center,

David C. Metz, MD, PhD, associate chief for Clinical Affairs, Gastrointestinal Division, Penn Medicine, University of Pennsylvania, discusses the utility of somatostatin analogs and emerging agents in the landscape of neuroendocrine tumors (NETs).

Ruth O&rsquo;Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treating premenopausal women with breast cancer.

Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medicine, and biological sciences chair, department of medicine, discusses PARP inhibitors for the treatment of lung cancer.

Frankie Ann Holmes, MD, Texas Oncology, discusses challenges with neoadjuvant endocrine therapy in breast cancer.

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses choosing second-line therapy for patients with urothelial carcinoma.

Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, Chair, Department of Medicine, discusses the current role of checkpoint inhibitors for the treatment of head and neck cancer during the ESMO 2017 Congress.

Neoadjuvant Therapy for HER2+ Early Breast Cancer